Liver Transplant Rejection Types and Management

Introduction to Liver Transplant Rejection

Liver transplant rejection can be classified into three main types: acute cellular rejection, chronic rejection, and antibody-mediated rejection, each with distinct pathological features and clinical implications 1, 2

Occurs in approximately 10% of liver transplant recipients, most commonly within the first 3 months post-transplantation but can occur at any time 1, 3
Clinical presentation includes abnormal liver function tests, fever, jaundice, and abdominal pain in advanced cases 1, 3
Often associated with low calcineurin inhibitor (CNI) levels and medication non-compliance, especially when occurring years after transplantation 1
First-line treatment consists of high-dose corticosteroids, typically administered as intravenous methylprednisolone 2, 3

Characterized by fibrosis and progressive disappearance of bile ducts (vanishing bile duct syndrome or ductopenic rejection) 1, 2
Results in severe biliary obstruction, jaundice, and is frequently associated with renal dysfunction 1
Treatment options include increasing CNI levels or adding sirolimus/everolimus to baseline immunosuppression 1, 2
Retransplantation should be considered if significant allograft synthetic dysfunction or portal hypertensive complications exist 1, 2
The rate of graft loss due to ductopenic rejection has significantly decreased to less than 2% with modern immunosuppression regimens 2

Monitoring for donor-specific antibodies (DSAs) may help identify patients at risk of antibody-mediated rejection 2
For persistent AMR not responding to first-line therapy, rituximab (to deplete B cells) or eculizumab (to inhibit complement activation) can be considered 2

Patients with autoimmune liver diseases are at higher risk for early and late cellular rejection 3
CMV viremia is a risk factor for chronic rejection 2
Medication adherence is critical, as non-compliance is associated with late rejection episodes 3

Liver biopsy remains the gold standard for definitive diagnosis of all types of rejection 2, 3
It is crucial to differentiate rejection from other causes of allograft dysfunction, including viral hepatitis, recurrent primary liver disease, vascular complications, and biliary complications 1, 4
Drug interactions with immunosuppressants are common and can lead to subtherapeutic levels; avoid medications that alter CNI metabolism through cytochrome P-450 3A4 and P-glycoprotein pathways 1, 3
Regular monitoring of liver function tests and immunosuppressant drug levels is essential for early detection and management of rejection 3